NYSE:TMO
THERMO FISHER SCIENTIFIC INC.
A premier global provider of life science tools, diagnostics, and analytical instruments that empowers innovation in pharmaceutical R&D and clinical testing.
Key Metrics
Investment Thesis
Bull Case
As a non-cyclical leader in the life sciences sector, Thermo Fisher is well-positioned to benefit from secular growth trends in biotechnology and personalized medicine. Strong free cash flow generation supports consistent dividend growth and substantial buybacks, enhancing shareholder value over time. The company's diverse product portfolio mitigates single-market risks while maintaining high gross margins typical of proprietary scientific equipment.
Bear Case
Valuation multiples may be stretched given the high price-to-earnings ratios common in healthcare infrastructure stocks with limited immediate catalysts for massive revenue acceleration. Dependence on commercial payers exposes the business to potential reimbursement rate cuts and pricing pressures that could compress profitability in the near term. High goodwill of $49.36B creates vulnerability to impairment charges if organic growth slows or integration costs from acquisitions like the recent $4.04B deal exceed expectations.
About THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific is a global leader in life science tools, diagnostics, separation sciences, and analytical instrumentation serving pharmaceutical, biotechnology, and healthcare markets. The company drives innovation through extensive research and development investments while maintaining a robust portfolio of high-margin scientific equipment and consumables. With over $44 billion in revenue, Thermo Fisher supports critical advancements in drug discovery, manufacturing, and patient care across the Americas, Europe, and Asia.
Analysis
Management Discussion
Recent financial performance demonstrates resilience with revenue reaching $44.56B in 2025, slightly up from the prior year despite a dip in 2023 and 2024. Net income has stabilized at $6.72B, reflecting effective cost management and strong operational cash flow of $7.82B. The company continues to balance capital expenditures for growth with significant share repurchases totaling $3.00B.
Industry Overview
The life sciences industry is characterized by long sales cycles, high regulatory barriers to entry, and a shift towards precision medicine requiring advanced analytical tools. Competition is fierce among multinational corporations, but market leaders with comprehensive platforms tend to capture disproportionate market share due to customer loyalty. Technological advancements in genomics and protein science continue to drive demand for specialized instrumentation and reagents.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $44.91B | $42.86B | $42.88B | $44.56B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $44.91B | $42.86B | $42.88B | $44.56B |
| Operating Expenses | $36.52B | $36.00B | $35.54B | $36.81B |
| Operating Income | $8.39B | $6.86B | $7.34B | $7.75B |
| R&D | $1.47B | $1.34B | $1.39B | $1.40B |
| G&A | $8.99B | $8.45B | $8.60B | $8.73B |
| Stock-Based Comp | $307.0M | $278.0M | $301.0M | $310.0M |
| Depreciation | $986.0M | $1.07B | $1.16B | $1.05B |
| Amortization | $2.40B | $2.34B | $1.95B | $1.73B |
| Other OpEx | $26.06B | $26.22B | $25.56B | $26.68B |
| Non-Operating Income | $-558.0M | $-561.0M | $-300.0M | $-438.0M |
| Interest Expense | $726.0M | $1.38B | — | — |
| Interest Income | $272.0M | $879.0M | $1.08B | $993.0M |
| Pre-Tax Income | $7.83B | $6.30B | $7.04B | $7.31B |
| Income Tax | $703.0M | $284.0M | $657.0M | $547.0M |
| Continuing Ops | $7.13B | $6.01B | $6.38B | $6.76B |
| Discontinued Ops | $-172.0M | $-59.0M | $-42.0M | $-40.0M |
| Net Income | $6.96B | $5.96B | $6.34B | $6.72B |
| Minority Interest | $10.0M | $-40.0M | $3.0M | $17.0M |
| Net to Common | $6.95B | $6.00B | $6.33B | $6.70B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $25.23B | $24.59B | $22.14B | $28.71B |
| Cash & Equivalents | $8.52B | $8.08B | $4.01B | $9.85B |
| Marketable Securities | — | — | $1.56B | $253.0M |
| Accounts Receivable | $8.12B | $8.22B | $8.19B | $8.90B |
| Inventory | $5.63B | $5.09B | $4.98B | $5.42B |
| Other Current Assets | $2.96B | $3.20B | $3.40B | $4.28B |
| Long-Term Assets | $71.92B | $74.14B | $75.18B | $81.64B |
| PP&E (Net) | $9.28B | $9.45B | $9.31B | $10.56B |
| Intangibles | $17.44B | $16.67B | $15.53B | $15.84B |
| Goodwill | $41.20B | $44.02B | $45.85B | $49.36B |
| Operating Leases | $1.59B | $1.56B | $1.49B | $1.45B |
| Other LT Assets | $2.04B | $1.95B | $2.65B | $4.25B |
| Total Assets | $97.15B | $98.73B | $97.32B | $110.34B |
| Current Liabilities | $17.01B | $14.01B | $13.33B | $15.19B |
| Accounts Payable | $3.38B | $2.87B | $3.08B | $3.62B |
| Current Leases | $272.0M | $263.0M | $261.0M | $275.0M |
| Deferred Revenue | $2.60B | $2.69B | $2.85B | $2.71B |
| Other Current Liab | $10.76B | $8.19B | $7.14B | $8.58B |
| Long-Term Liabilities | $36.11B | $37.99B | $34.44B | $41.74B |
| LT Operating Leases | $1.31B | $1.24B | $1.24B | $1.20B |
| Other LT Liab | $33.62B | $35.25B | $32.06B | $39.36B |
| Total Liabilities | $53.12B | $52.00B | $47.77B | $56.93B |
| Shareholders' Equity | $44.03B | $46.72B | $49.55B | $53.41B |
| Retained Earnings | $41.91B | $47.36B | $53.10B | $59.16B |
| AOCI | $-3.10B | $-3.22B | $-2.70B | $-2.45B |
| Total L&E | $97.15B | $98.73B | $97.32B | $110.34B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $6.96B | $5.96B | $6.34B | $6.72B |
| Non-Cash Adjustments | $-1.10B | $1.40B | $524.0M | $-1.14B |
| Working Capital Changes | $3.30B | $1.05B | $1.80B | $2.23B |
| Cash from Operations | $9.15B | $8.41B | $8.67B | $7.82B |
| Capital Expenditures | $2.24B | $1.48B | $1.40B | $1.52B |
| Cash from Investing | $-2.16B | $-5.14B | $-5.84B | $-4.05B |
| Debt Issuances | $3.19B | $5.94B | $1.20B | $7.76B |
| Debt Repayments | $375.0M | $5.78B | $3.61B | $2.41B |
| Share Buybacks | $3.00B | $3.00B | $4.00B | $3.00B |
| Dividends Paid | $455.0M | $523.0M | $583.0M | $636.0M |
| Cash from Financing | $-2.81B | $-3.62B | $-6.79B | $1.80B |
| FX Effect | $-139.0M | $-82.0M | $-91.0M | $267.0M |
| Net Change in Cash | $4.05B | $-440.0M | $-4.06B | $5.84B |
| Beginning Cash | $4.49B | $8.54B | $8.10B | $4.04B |
| Ending Cash | $8.54B | $8.10B | $4.04B | $9.88B |
Frequently Asked Questions
How does THERMO FISHER SCIENTIFIC INC. make money?
The company's revenue is primarily driven by its Life Sciences segment covering laboratory equipment and consumables, Separation Sciences providing chromatography solutions for purification processes, Clinical Diagnostics offering point-of-care testing devices, and Analytical Instrumentation delivering mass spectrometry and spectroscopy systems for quality control.
What are the main risks for TMO?
Regulatory headwinds from the U.S. Inflation Reduction Act could impact pricing power on consumables and diagnostic tests sold to government payers. Geopolitical tensions and supply chain disruptions may delay product launches or increase costs for raw materials sourced from Asia. Currency fluctuations in a highly international business model can erode reported earnings if the dollar strengthens against foreign currencies.
What is TMO's competitive advantage?
Thermo Fisher benefits from an unparalleled global footprint with a vast distribution network that ensures rapid delivery of time-sensitive reagents. The firm maintains high switching costs due to deep integration with customers' R&D workflows and proprietary technologies in specialized fields like proteomics. Its massive scale allows for significant vertical integration and consistent investment in R&D, creating a durable moat against smaller competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.